Verfahren und Kits zur Erzeugung von Angeborenen Mimetischen Immunzellen aus Pluripotenten Stammzellen

Details

Veröffentlichungs-Nr.

EP4736957

Anmeldetag

7. Februar 2018

Veröffentlichung

6. Mai 2026

Rechtsraum

EP

IPC

A61P35/00(BECK ROSE C et al.)(RIKEN et al.)(KAUFMAN DAN S et al.)(FATE THERAPEUTICS INC et al.)

Abstract

Human pluripotent stem cells (hPSCs), especially induced pluripotent stem cells (iPSCs) provide a promising starting material to produce mimetic innate immune cells such as natural killer (NK) cells and γδ T-cells for cancer immunotherapy. To facilitate consistent mass production, an overall manufacturing scheme to make mimetic innate immune cells from hPSCs was designed and demonstrated. Particularly, a robust protocol to differentiate hPSCs into NK cells or γδ T-cells through sequential hematopoietic differentiation on stromal cell line deficient in expressing M-CSF and lymphoid commitment on stromal cell line deficient in expressing M-CSF ectopically expressing DLL1 without employing CD34+ cell enrichment and spin embryoid body formation is established. Using this two-stage protocol, the generation of functional mimetic NK cells and functional mimetic γδ NKT-cells was demonstrated from hPSCs, including hESCs, peripheral blood cell-derived iPSCs (PBC-iPSCs), non-T cell-derived iPSCs or γδ T cell-derived iPSCs and the use of these mimetic innate immune cells in killing cancer cells.

Anmelder

Firma

Agency for Science, Technology and Research

Land

🇸🇬 Singapur